8-K: Pulmonx Achieves Record Revenue in Second Quarter 2024, Driven by U.S. Growth

Pulmonx reported record worldwide revenue of $20.8 million for the second quarter of 2024, a 21% increase year-over-year, fueled by strong U.S. sales.

Summary

• Pulmonx Corporation announced its financial results for the second quarter of 2024, ending June 30, 2024.
• The company achieved record worldwide revenue of $20.8 million, a 21% increase compared to the same period last year.
• U.S. revenue reached $13.9 million, showing a 26% year-over-year growth.
• International revenue was $6.9 million, a 12% increase compared to the second quarter of 2023.
• Gross profit for the quarter was $15.3 million, with a gross margin of 74%.
• Operating expenses increased by 6% to $30.9 million, including a one-time, non-cash charge of $1.7 million for software impairment.
• The net loss for the quarter was $15.3 million, or $0.39 per share, an improvement from a net loss of $16.2 million, or $0.43 per share, in the same period last year.
• Adjusted EBITDA loss was $7.6 million, compared to $10.3 million in the second quarter of 2023.
• Pulmonx maintains its full-year 2024 revenue guidance of $81 million to $84 million and a gross margin of 74% to 75%.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong revenue growth and improved EBITDA, but tempered by the continued net loss and high operating expenses. The company is showing good progress but still has challenges to overcome.

Positives

• The company experienced strong revenue growth, particularly in the U.S. market.
• The gross margin remained consistent at a high level of 74%.
• Pulmonx is expanding its reach by adding new treatment centers.
• The company is making progress with its AeriSeal System clinical trial.
• The adjusted EBITDA loss improved year-over-year, indicating better cost management.
• The company has a strong cash position with $114.5 million in cash, cash equivalents, and marketable securities.

Negatives

• The company reported a net loss of $15.3 million for the quarter.
• Operating expenses increased by 6% due to a one-time software impairment charge of $1.7 million.
• The company is still operating at a loss, although the loss has decreased compared to the previous year.

Risks

• The company's future performance is subject to risks and uncertainties, as detailed in their SEC filings.
• The company's ability to achieve its projected growth depends on the continued adoption of its Zephyr Valve procedures.
• The company's operating expenses are still high, impacting overall profitability.

Future Outlook

Pulmonx expects full-year 2024 revenue to be in the range of $81 million to $84 million, with a gross margin between 74% and 75%. Total operating expenses are expected to be between $127 million and $129 million, including $25 million of non-cash stock-based compensation.

Management Comments

• Steve Williamson, President and CEO, stated that the record quarterly results reflect the continued traction of their commercial strategy, particularly in the United States.
• Management expressed confidence in their ability to deliver projected growth through the balance of the year and beyond.

Industry Context

Pulmonx operates in the medical device industry, specifically focusing on minimally invasive treatments for lung diseases like COPD. The company's growth is driven by the adoption of its Zephyr Valve technology, which is becoming a standard of care for severe emphysema. The company is competing with other medical device companies in the respiratory space, and its success depends on continued innovation and market penetration.

Comparison to Industry Standards

• Pulmonx's 21% revenue growth is strong compared to the overall medical device industry, which typically sees single-digit growth rates.
• Companies like Medtronic and Boston Scientific, which also operate in the medical device space, have reported varying growth rates, but Pulmonx's focus on a specific niche market allows for more targeted growth.
• The 74% gross margin is also competitive, indicating efficient operations and pricing strategies.
• However, the company's continued net losses highlight the challenges of scaling a medical device business, which often requires significant upfront investment in research, development, and sales infrastructure.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and improved EBITDA positively.
• Employees may be encouraged by the company's progress and expansion.
• Customers (physicians and patients) will benefit from the increased availability of Zephyr Valve treatments.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company's improved financial performance favorably.

Next Steps

• Pulmonx will continue to focus on expanding its commercial presence, particularly in the U.S.
• The company plans to launch new pilot programs to optimize patient workflows.
• Pulmonx will continue to build local awareness of its Zephyr Valves.
• The company will present eight scientific abstracts at upcoming industry conferences.
• Pulmonx will host a conference call to discuss the second quarter financial results.

Key Dates

Keywords

Pulmonx, Zephyr Valve, Revenue, Financial Results, COPD, AeriSeal System, Gross Margin, EBITDA, Medical Devices, Lung Disease